Kevin Kist, DO
Pulmonary Disease · Williamsport, PANPI 1073577383
Payments from drug & device makers
Across 33 payments — averaging $34.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$269
- Boehringer Ingelheim$162
- Mylan Specialty L.p.$145
- Regeneron Healthcare Solutions, Inc.$105
- Actelion Pharmaceuticals US, Inc.$92
- Inspire Medical Systems, Inc.$81
- plus $289 from 10 others
What the payments were for
- Food & beverage$1,144100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $269 |
| Boehringer Ingelheim | 3 | $162 |
| Mylan Specialty L.p. | 2 | $145 |
| Regeneron Healthcare Solutions, Inc. | 2 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| Inspire Medical Systems, Inc. | 2 | $81 |
| AstraZeneca | 4 | $77 |
| Grifols USA, LLC | 2 | $46 |
| Baxter Healthcare | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $24 |
| Boston Scientific | 1 | $18 |
| Harmony Biosciences LLC | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,144 in reported general payments places this provider in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $256,589 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 168 | $139,022 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 191 | $94,556 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $54,469 |
| NucalaMepolizumab | 14 | $51,848 |
| XolairOmalizumab | 18 | $36,347 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $26,800 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $26,784 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $26,361 |
| Arnuity ElliptaFluticasone Furoate | 66 | $14,797 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $13,822 |
| Spiriva RespimatTiotropium Bromide | 19 | $11,160 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $9,859 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $6,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 185 | $6,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $269 | $368,514604 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $162 | $320,895142 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $77 | $32,14454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Williamsport
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.